摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

格列吡嗪杂质3 | 933705-21-6

中文名称
格列吡嗪杂质3
中文别名
——
英文名称
2-aminoethylbenzenesulfonamide
英文别名
2-(2-Aminoethyl)benzenesulfonamide
格列吡嗪杂质3化学式
CAS
933705-21-6
化学式
C8H12N2O2S
mdl
——
分子量
200.261
InChiKey
XNMHWEWCCHMGDY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.2
  • 重原子数:
    13
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    94.6
  • 氢给体数:
    2
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    吡啶-2-甲醛格列吡嗪杂质3sodium hydroxide三乙酰氧基硼氢化钠 作用下, 以 乙醇1,2-二氯乙烷 为溶剂, 以57%的产率得到4-(2-(bis(pyridin-2-ylmethyl)amino)ethyl)benzenesulfonamide
    参考文献:
    名称:
    INHIBITORS OF CARBONIC ANHYDRASE IX
    摘要:
    具有在诊断成像和治疗过度表达CA-IX疾病中有用的新型放射性药物,包括一种含有磺胺基团的复合物,该基团能够结合CA-IX的活性催化位点,以及适用于放射成像和/或放射治疗的放射性核素:
    公开号:
    US20090175794A1
点击查看最新优质反应信息

文献信息

  • Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents
    申请人:Ohrai Kazuhiko
    公开号:US20080004262A1
    公开(公告)日:2008-01-03
    This invention relates to benzopyran derivatives of formula (I) or (II), or pharmaceutically acceptable salts thereof wherein R 1 and R 2 are independently of each other hydrogen atom, C 1-6 alkyl group or C 6-14 aryl group, R 3 is hydrogen atom or C 1-6 alkylcarbonyloxy group, or together with R 4 forms a bond, R 4 is hydrogen atom, or together with R 3 forms a bond, m is an integer of 0 to 4, n is an integer of 0 to 4, V is a single bond, CR 7 R 8 , NR 9 , O, S, SO or SO 2 , R 5 is hydrogen atom or C 1-6 alkyl group, R 6 is hydrogen atom, C 1-6 alkyl group, C 3-8 cycloalkyl group, C 3-8 cycloalkenyl group, amino group, C 1-6 alkylamino group, di-C 1-6 alkylamino group, C 6-14 arylamino group, C 2-9 heteroarylamino group, C 6-14 aryl group, C 2-9 heteroaryl group or C 2-9 heterocyclyl group, A is 5-, 6- or 7-member ring fused with benzene ring, as constituent atom of the ring, oxygen atom, nitrogen atom or sulfur atom may be contained in the number of 1 to 3 alone or in a combination thereof, the number of unsaturated bond in the ring is 1, 2 or 3 including an unsaturated bond of the benzene ring to be fused, carbon atoms constituting the ring may be carbonyl or thiocarbonyl. These compounds are useful as an anti-arrhythmic agent.
    本发明涉及式(I)或(II)的苯并喃衍生物,或其药学上可接受的盐,其中R1和R2独立地为氢原子,C1-6烷基或C6-14芳基;R3为氢原子或C1-6烷基羰氧基,或与R4一起形成键;R4为氢原子,或与R3一起形成键;m为0至4的整数,n为0至4的整数,V为单键,CR7R8,NR9,O,S,SO或SO2;R5为氢原子或C1-6烷基,R6为氢原子,C1-6烷基,C3-8环烷基,C3-8环烯基,基,C1-6烷基基,二C1-6烷基基,C6-14芳基基,C2-9杂芳基基,C6-14芳基,C2-9杂芳基或C2-9杂环烷基;A为与苯环融合的5、6或7元环,作为环的组成原子,其中单独或组合存在1至3个氧原子、氮原子或原子,环中不饱和键的数量为1、2或3,包括与苯环融合的不饱和键,构成环的碳原子可以是羰基或代羰基。这些化合物可用作抗心律失常药物。
  • Tricyclic benzopyrane compound
    申请人:Ohrai Kazuhiko
    公开号:US20100069374A1
    公开(公告)日:2010-03-18
    This invention relates to benzopyran derivatives of formula (I) or (II), or pharmaceutically acceptable salts thereof wherein R 1 and R 2 are independently of each other hydrogen atom, C 1-6 alkyl group or C 6-14 aryl group, R 3 is hydrogen atom or C 1-6 alkylcarbonyloxy group, or together with R 4 forms a bond, R 4 is hydrogen atom, or together with R 3 forms a bond, m is an integer of 0 to 4, n is an integer of 0 to 4, V is a single bond, CR 7 R 8 , NR 9 , O, S, SO or SO 2 , R 5 is hydrogen atom or C 1-6 alkyl group, R 6 is hydrogen atom, C 1-6 alkyl group, C 3-8 cycloalkyl group, C 3-8 cycloalkenyl group, amino group, C 1-6 alkylamino group, di-C 1-6 alkylamino group, C 6-14 arylamino group, C 2-9 heteroarylamino group, C 6-14 aryl group, C 2-9 heteroaryl group or C 2-9 heterocyclyl group, A is 5-, 6- or 7-member ring fused with benzene ring, as constituent atom of the ring, oxygen atom, nitrogen atom or sulfur atom may be contained in the number of 1 to 3 alone or in a combination thereof, the number of unsaturated bond in the ring is 1, 2 or 3 including an unsaturated bond of the benzene ring to be fused, carbon atoms constituting the ring may be carbonyl or thiocarbonyl. These compounds are useful as an anti-arrhythmic agent.
    本发明涉及公式(I)或(II)的苯并喃衍生物或其药学上可接受的盐, 其中R1和R2独立地是氢原子,C1-6烷基或C6-14芳基,R3是氢原子或C1-6烷基羰氧基,或与R4一起形成键,R4是氢原子,或与R3一起形成键,m是0到4的整数,n是0到4的整数,V是单键,CR7R8,NR9,O,S,SO或SO2,R5是氢原子或C1-6烷基,R6是氢原子,C1-6烷基,C3-8环烷基,C3-8环烯基,基,C1-6烷基基,双C1-6烷基基,C6-14芳基基,C2-9杂芳基基,C6-14芳基,C2-9杂芳基或C2-9杂环烷基,A是与苯环融合的5、6或7成员环,作为环的组成原子,其中含有1到3个氧原子,氮原子或原子,或其组合,环中不饱和键的数量为1、2或3,包括与苯环融合的不饱和键,构成环的碳原子可以是羰基或代羰基。这些化合物可用作抗心律失常剂。
  • Cu(II) Complexes of New Sulfa Drug Schiff Base Ligands: Synthesis, Structural Characterization, Antimicrobial Activities, and Time-Killing Kinetics
    作者:Hakan Şahal、Önder İdil、Erdal Canpolat、Mustafa Özkan
    DOI:10.1134/s1068162023030184
    日期:2023.6
    Abstract Synthesis of three different new sulfonamide compounds (L1–L3) and their Cu(II) complexes were carried out. Their structures were characterized by spectroscopic methods such as Fourier transform infrared, Proton nuclear magnetic resonance and elemental analysis. Cu(II) complexes were screened for Gram-positive, Gram-negative bacteria and against yeast using the microdilution method. In particular
    摘要 合成了三种不同的新型磺胺化合物 (L 1 –L 3 ) 及其 Cu(II) 络合物。它们的结构通过傅里叶变换红外、质子核磁共振和元素分析等光谱方法表征。使用微量稀释法筛选 Cu(II) 配合物的革兰氏阳性菌、革兰氏阴性菌和酵母菌。特别是,发现CuL 2对革兰氏 (–)、革兰氏 (+) 和真核酵母具有显着的抗菌作用。结果表明,CuL 2表现出比其他配合物更好的抗菌活性。根据抗菌活性结果,CuL 2的时间杀灭实验, 最有效的复杂, 被执行了。
  • CHROMATOGRAPHIC RESINS AND METHODS FOR USING SAME
    申请人:MASSEY UNIVERSITY
    公开号:EP0783366A1
    公开(公告)日:1997-07-16
  • Benzopyran compounds useful for the treatment of arrhytmia
    申请人:Nissan Chemical Industries, Ltd.
    公开号:EP1718629B1
    公开(公告)日:2012-12-26
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫